{"id":49185,"date":"2025-11-27T21:39:35","date_gmt":"2025-11-27T13:39:35","guid":{"rendered":"https:\/\/flcube.com\/?p=49185"},"modified":"2025-11-27T21:39:37","modified_gmt":"2025-11-27T13:39:37","slug":"sprint-bioscience-sells-trex1-program-to-gilead-for-14m-upfront","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49185","title":{"rendered":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront"},"content":{"rendered":"\n<p><strong>Sprint Bioscience AB<\/strong> announced the sale of its <strong>TREX1 cancer program<\/strong> to <strong>Gilead Sciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) for an <strong>upfront payment of USD\u202f14\u202fmillion<\/strong>, plus potential <strong>clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion<\/strong>, marking a significant exit for the Swedish oncology specialist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-terms\">Transaction Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Seller<\/strong><\/td><td>Sprint Bioscience AB<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>Gilead Sciences, Inc.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>TREX1 cancer program (small molecule, first\u2011in\u2011class)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f14\u202fmillion<\/td><\/tr><tr><td><strong>Milestone Potential<\/strong><\/td><td>Up to USD\u202f400\u202fmillion (clinical, regulatory, commercial)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD\u202f414\u202fmillion<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Fragment\u2011based drug development platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sprint-bioscience-profile\">Sprint Bioscience Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> Specialized in <strong>first\u2011in\u2011class small molecule oncology programs<\/strong><\/li>\n\n\n\n<li><strong>Platform:<\/strong> <strong>Fragment\u2011based drug development<\/strong> methodology for time\u2011 and resource\u2011efficient discovery<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> TREX1 represents flagship program; company retains other early\u2011stage assets<\/li>\n\n\n\n<li><strong>Strategy:<\/strong> Out\u2011license clinical\u2011stage programs to global pharma partners<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-rationale\">Market Context &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Global Market Size (2024)<\/th><th>Growth CAGR<\/th><th>Competitive Landscape<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology Small Molecules<\/strong><\/td><td>$68\u202fbillion<\/td><td>8%<\/td><td>Gilead expanding pipeline beyond cell therapy<\/td><\/tr><tr><td><strong>Fragment\u2011Based Discovery<\/strong><\/td><td>$2.1\u202fbillion (services)<\/td><td>12%<\/td><td>Sprint\u2019s platform validated by Gilead deal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gilead\u2019s Strategy:<\/strong> Strengthens oncology portfolio after <strong>Trodelvy<\/strong> and <strong>Yescarta<\/strong>; adds novel DNA damage response target (TREX1)<\/li>\n\n\n\n<li><strong>Sprint\u2019s Validation:<\/strong> Deal confirms <strong>fragment\u2011based approach<\/strong> can yield pharma\u2011ready assets; likely to drive partnership interest in remaining pipeline<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> Upfront payment covers <strong>18\u201124 months<\/strong> of Sprint\u2019s operating expenses; milestones provide <strong>path to >$500\u202fM<\/strong> valuation if achieved<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievement probabilities and Sprint\u2019s future partnership strategy. Actual results may differ materially due to clinical trial risks, Gilead development priorities, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":49188,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,226,1025,4479],"class_list":["post-49185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-gilead-sciences","tag-nasdaq-gild","tag-sprint-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49185\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront\" \/>\n<meta property=\"og:description\" content=\"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49185\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T13:39:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T13:39:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront\",\"datePublished\":\"2025-11-27T13:39:35+00:00\",\"dateModified\":\"2025-11-27T13:39:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185\"},\"wordCount\":279,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2706.webp\",\"keywords\":[\"Cancer\",\"Gilead Sciences\",\"NASDAQ: GILD\",\"Sprint Bioscience\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49185#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49185\",\"name\":\"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2706.webp\",\"datePublished\":\"2025-11-27T13:39:35+00:00\",\"dateModified\":\"2025-11-27T13:39:37+00:00\",\"description\":\"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49185\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49185#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront - Insight, China&#039;s Pharmaceutical Industry","description":"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49185","og_locale":"en_US","og_type":"article","og_title":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront","og_description":"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.","og_url":"https:\/\/flcube.com\/?p=49185","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T13:39:35+00:00","article_modified_time":"2025-11-27T13:39:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49185#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49185"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront","datePublished":"2025-11-27T13:39:35+00:00","dateModified":"2025-11-27T13:39:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49185"},"wordCount":279,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","keywords":["Cancer","Gilead Sciences","NASDAQ: GILD","Sprint Bioscience"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49185#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49185","url":"https:\/\/flcube.com\/?p=49185","name":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49185#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","datePublished":"2025-11-27T13:39:35+00:00","dateModified":"2025-11-27T13:39:37+00:00","description":"Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc. (NASDAQ: GILD) for an upfront payment of USD\u202f14\u202fmillion, plus potential clinical, regulatory, and commercial milestone payments totaling up to USD\u202f400\u202fmillion, marking a significant exit for the Swedish oncology specialist.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49185#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49185"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49185#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","width":1080,"height":608,"caption":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49185#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49185"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49185\/revisions"}],"predecessor-version":[{"id":49190,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49185\/revisions\/49190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}